Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Aldeyra Therapeutics, Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 5 distinct examiners and 5 distinct art units, so each listed matter has a separate examiner and unit assignment.
OH, TAYLOR V is the busiest examiner, with 1 pending matter. The data supports matter-specific prosecution planning, with portfolio-level attention directed toward consistency in technical descriptions and claim strategy rather than reliance on a common examiner practice.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OH, TAYLOR V | 1 | 81.3% | +15.3% |
| BARSKY, JARED | 1 | 50.3% | +22.8% |
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.8% |
| AZPURU, CARLOS A | 1 | 83.8% | +10.8% |
| VALLE, ERNESTO | 1 | 65.8% | +32.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18904373 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | OH, TAYLOR V | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18391167 | METHOTREXATE TREATMENT METHODS | AZPURU, CARLOS A | — |
| 18007661 | DRY EYE DISEASE BIOMARKERS AND THEIR USE FOR TREATMENT | VALLE, ERNESTO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18904373 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | OH, TAYLOR V | — |
| 18850826 | METHODS OF TREATING SJÖGREN-LARSSEN SYNDROME | BARSKY, JARED | — |
| 18786975 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MACULAR DEGENERATION | HUANG, GIGI GEORGIANA | — |
| 18391167 | METHOTREXATE TREATMENT METHODS | AZPURU, CARLOS A | — |
| 18007661 | DRY EYE DISEASE BIOMARKERS AND THEIR USE FOR TREATMENT | VALLE, ERNESTO | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1628 | 1 |
| 1613 | 1 |
| 1617 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18904373 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | OH, TAYLOR V | 1625 | §112 | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18850826 | METHODS OF TREATING SJÖGREN-LARSSEN SYNDROME | BARSKY, JARED | 1628 | §102§103§112DP | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18786975 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MACULAR DEGENERATION | HUANG, GIGI GEORGIANA | 1613 | Other | Non-Final OA | — | Pending | Jul 29, 2024 |
| 18391167 | METHOTREXATE TREATMENT METHODS | AZPURU, CARLOS A | 1617 | §103§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18007661 | DRY EYE DISEASE BIOMARKERS AND THEIR USE FOR TREATMENT | VALLE, ERNESTO | 1623 | §103§112 | Non-Final OA | — | Pending | Dec 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAldeyra Therapeutics, Inc. has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Taylor V Oh has the most, with 1 of Aldeyra Therapeutics, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
